ATRX and central nervous system cancer: Next, we extended our integrative approach to include proteomic analyses of two distinct molecular subtypes of WHO grade-II gliomas, namely IDH-mutant 1p/19q co-deleted ATRX-wt WHO grade-II DGs (n = 3 vs. n = 6, A/G and A/A, respectively) and IDH-mutant 1p/19q-intact ATRX-mut WHO grade-II DGs (n = 3 vs. n = 4, A/G and A/A, respectively).